Drug Profile
Research programme: vascular disorder therapeutics - Vasomune Therapeutics
Alternative Names: VasculotideLatest Information Update: 03 Jan 2020
Price :
$50
*
At a glance
- Originator Vasomune Therapeutics
- Class Peptides
- Mechanism of Action TIE-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute kidney injury; Vascular disorders
Most Recent Events
- 03 Jan 2020 AnGes MG is now called AnGes
- 28 Nov 2018 No recent reports of development identified for preclinical development in Acute kidney injury in Canada
- 28 Nov 2018 No recent reports of development identified for preclinical development in Vascular-disorders in Canada